Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas
Jerrold L. Boxerman(University of California, Los Angeles), Chas Haynes, Bradley J. Erickson(University of California, Los Angeles), Al Musella(Harvard University), Martin J. van den Bent(Erasmus MC Cancer Institute), Daniel P. Barboriak(Duke University), Lalitha Shankar(University of California, Los Angeles), Michael Weller(University of Zurich), Evanthia Galanis(The University of Texas at San Antonio Health Science Center), Patrick Y. Wen(Dana-Farber Brigham Cancer Center), Benjamin M. Ellingson(University of California, Los Angeles), Kathleen M. Schmainda(American College of Radiology), Jayashree Kalpathy–Cramer(Portland State University), Marion Smits(Erasmus MC), Ann E Kingston(Mayo Clinic), C. Chad Quarles(Barrow Neurological Institute), Leland Hu(Alliance for Clinical Trials in Oncology), Timothy J. Kaufmann(Mayo Clinic), Paula Jacobs(University of California, Los Angeles), Timothy F. Cloughesy(University of California, Los Angeles), Mark R. Gilbert(National Institutes of Health), David Sandak, Caroline Chung(University of California, Los Angeles), Wolfgang Wick(Hertie Institute for Clinical Brain Research), Elizabeth R. Gerstner(University of California, Los Angeles), Wai Kuen Yung(University of California, Los Angeles), Raymond Huang(Brigham and Women's Hospital), Susan M. Chang(University of California, San Francisco), Bruce R. Rosen(Massachusetts General Hospital), David F. Arons, M. Z. Wallace
Cited by 190
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Recommended implementation of arterial spin‐labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia
|Magnetic Resonance in Medicine|2014|2.2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k